A phase I study to assess the safety and tolerability of intravesical pembrolizumab in recurrent non-muscle invasive bladder cancer (NMIBC).

Woodcock VK., Purshouse K., Butcher C., Haddon C., Verrall G., Elhussein L., Salio M., Middleton MR., Cerundolo V., Crew J., Protheroe A.

DOI

10.1200/JCO.2019.37.7_suppl.406

Type

Conference paper

Publication Date

01/03/2019

Volume

37

Permalink Original publication